Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients.
BACKGROUND
Deficiencies in components of the classical pathway of complement activation are strong risk factors for lupus erythematosus (LE).Yet, it has not been addressed whether the conventional measurements of the serum hemolytic CH50 activity and antigenic concentrations of C3 and C4 are sufficient to asses a deficiency in C4A, C4B or C2 components, the most common deficiencies associated with LE.


METHODS
In a retrospective series, we performed complement analyses in 35 patients with LE who were systematically screened for a complement deficiency. The majority of patients had cutaneous LE with mild systemic involvement and no complement consumption. Of 25 patients (72%) with complement deficiency we found 13 with a partial C4A deficiency, 2 with a complete C4A deficiency, 6 with a partial C4B deficiency, 2 with a complete C4B deficiency and 2 with a combined partial C2 and C4A deficiency.


RESULTS
The total complement activity (CH50) was decreased in only one out of two patients with complete C4B deficiency. CH50 level was found to be low-normal (35-38 U/ml(-1)) in one patient with partial C4B deficiency, one patient with complete C4B deficiency and both patients with combined partial C4A and C2 deficiency. Total C4 levels were normal in 9 out of 13 the patients with a partial C4A deficiency and in 2 out of 6 patients with a complete C4B deficiency. The antigenic concentration of C3 was low in only 1 patients with a complete C4B deficiency and within the normal range in all the others patients. Overall, 50% of the patients had normal or elevated C3, C4, and CH50 levels.


CONCLUSIONS
This study emphasizes that the usual measurements of CH50, C3 and C4 levels are not adequate to detect a C4 and/or C2 deficiency in patients with LE. In epidemiologic or investigative studies addressing the prevalence of complement deficiency, more elaborated diagnostic tests, such as C4 protein allotyping, C2 level measurement and genetic screening for type I C2 deficiency should also be performed.
Boeckler
P
P
Clinique Dermatologique, 1, Place de l'Hôpital, F-67091 Strasbourg Cedex, France.
Meyer
A
A
Uring-Lambert
B
B
Goetz
J
J
Cribier
B
B
Hauptmann
G
G
Lipsker
D
D
D000328:Adult; D003176:Complement C3 / Q000032:analysis / Q000172:deficiency*; D003181:Complement C4 / Q000032:analysis / Q000172:deficiency*; D015941:Complement Hemolytic Activity Assay / Q000379:methods*; D003165:Complement System Proteins / Q000032:analysis / Q000172:deficiency*; D005260:Female; D014644:Genetic Variation; D006649:Histocompatibility Antigens / Q000032:analysis; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000276:immunology*; D008297:Male; D012189:Retrospective Studies
D003176:Complement C3; D003181:Complement C4; D006649:Histocompatibility Antigens; D003165:Complement System Proteins